Pyrrolo[3,4-c]pyridine-1,3(2H)-diones: A novel antimycobacterial class targeting mycobacterial respiration

Journal of Medicinal Chemistry

Volumn 58, Issue 23, 2015, Pages 9371-9381

  Van Der Westhuyzen, Renier ^a   Winks, Susan ^a   Wilson, Colin R ^a   Boyle, Grant A ^a   Gessner, Richard K ^a   Soares De Melo, Candice ^a   Taylor, Dale ^a   De Kock, Carmen ^a   Njoroge, Mathew ^a   Brunschwig, Christel ^a   Lawrence, Nina ^a   Rao, Srinivasa P S ^d   Sirgel, Frederick ^b   Van Helden, Paul ^b   Seldon, Ronnett ^a   Moosa, Atica ^a   Warner, Digby F ^a   Arista, Luca ^c   Manjunatha, Ujjini H ^d   Smith, Paul W ^d   Street, Leslie J ^a   Chibale, Kelly ^a   more..

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c NOVARTIS PHARMA AG   (Switzerland)

^d NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINO 2 BENZYL 4 METHYL 1,3 DIOXO 2,3 DIHYDRO 1H PYRROLO[3,4 C]PYRIDINE 6 CARBOXAMIDE; 7 AMINO 2 BENZYL 4 METHYL 1,3 DIOXO 2,3 DIHYDRO 1H PYRROLO[3,4 C]PYRIDINE 6 CARBOXYLIC ACID; 7 AMINO 2 BENZYL 4 METHYL 6 (3 METHYL 1,2,4 OXADIAZOL 5 YL) 1H PYRROLO[3,4 C]PYRIDINE 1,3 (2H) DIONE; 7 AMINO 2 BENZYL 4 METHYL 6 (5 METHYL 1,3,4 OXADIAZOL 2 YL) 1H PYRROLO[3,4 C]PYRIDINE 1,3 (2H) DIONE; 7 AMINO 2 BENZYL 4 METHYL 6 [3 (TRIFLUOROMETHYL) 1,2,4 OXADIAZOL 5 YL] 1H PYRROLO[3,4 C]PYRIDINE 1,3 (2H) DIONE; 7 AMINO 2 BENZYL N CYANO 4 METHYL 1,3 DIOXO 2,3 DIHYDRO 1H PYRROLO[ 3,4 C]PYRIDINE 6 CARBOXAMIDE; 7 AMINO 2 BENZYL N HYDROXY 4 METHYL 1,3 DIOXO 2,3 DIHYDRO 1H PYRROLO[ 3,4 C]PYRIDINE 6 CARBOXAMIDE; 7 AMINO 2 BENZYL N,4 DIMETHYL 1,3 DIOXO 2,3 DIHYDRO 1H PYRROLO[ 3,4 C]PYRIDINE 6 CARBOXAMIDE; 7 AMINO 2 BENZYL N,N, 4 TRIMETHYL 1,3 DIOXO 2,3 DIHYDRO 1H PYRROLO[ 3,4 C]PYRIDINE 6 CARBOXAMIDE; CYCLOPROPYL 7 AMINO 2 BENZYL 4 METHYL 1,3 DIOXO 2,3 DIHYDRO 1H PYRROLO[3,4 C]PYRIDINE 6 CARBOXYLIC ACID; CYTOCHROME C; METHYL 7 AMINO 2 BENZYL 4 METHYL 1,3 DIOXO 2,3 DIHYDRO 1H PYRROLO[3,4 C]PYRIDINE 6 CARBOXYLIC ACID; PROPYL 7 AMINO 2 BENZYL 4 METHYL 1,3 DIOXO 2,3 DIHYDRO 1H PYRROLO[3,4 C]PYRIDINE 6 CARBOXYLIC ACID; PYRROLO[3,4 C]PYRIDINE DERIVATIVE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; PYRIDONE DERIVATIVE; PYRROLE DERIVATIVE;

ANTIMICROBIAL ACTIVITY; ARTICLE; DELETION MUTANT; HIGH THROUGHPUT SCREENING; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; METABOLIC STABILITY; MICROSOME; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHARMACOKINETIC PARAMETERS; POINT MUTATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; HUMAN; METABOLISM; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE; RAT; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; ELECTRON TRANSPORT COMPLEX III; HUMANS; MICE; MICROSOMES, LIVER; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; PYRIDONES; PYRROLES; RATS; TUBERCULOSIS;

EID: 84949818262     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01542     Document Type: Article

References (30)

1. Global Tuberculosis Report 2014; World Health Organisation: Geneva; http://www.who.int/tb/publications/global-report/en/ (accessed July 9, 2015).
2. Zumla, A. I.; Gillespie, S. H.; Hoelscher, M.; Philips, P. P. J.; Cole, S. T.; Abubakar, I.; McHugh, T. D.; Schito, M.; Maeurer, M.; Nunn, A. J. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects Lancet Infect. Dis. 2014, 14, 327-340 10.1016/S1473-3099(13)70328-1
3. Dartois, V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells Nat. Rev. Microbiol. 2014, 12, 159-167 10.1038/nrmicro3200
4. Rattan, A.; Kalia, A.; Ahmad, N. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives Emerging Infect. Dis. 1998, 4, 195-209 10.3201/eid0402.980207
5. Wong, E. B.; Cohen, K. A.; Bishai, W. R. Rising to the challenge: new therapies for tuberculosis Trends Microbiol. 2013, 21, 493-501 10.1016/j.tim.2013.05.002
6. Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H. W. H.; Neefs, J.-M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis Science 2005, 307, 223-227 10.1126/science.1106753
7. Field, S. K. Safety and efficacy of delamanid in the treatment of multidrug-resistant tuberculosis (MDR-TB) Clin. Med. Insights: Ther. 2013, 5, 137-149 10.4137/CMT.S11675
8. Ryan, N. J.; Lo, J. H. Delamanid: first global approval Drugs 2014, 74, 1041-1045 10.1007/s40265-014-0241-5
9. Manjunatha, U. H.; Smith, P. W. Perspective: Challenges and opportunities in TB drug discovery from phenotypic screening Bioorg. Med. Chem. 2015, 23, 5087-5097 10.1016/j.bmc.2014.12.031
10. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The design of leadlike combinatorial libraries Angew. Chem., Int. Ed. 1999, 38, 3743-3748 10.1002/(SICI)1521-3773(19991216)38:24<3743::AID-ANIE3743>3.3.CO;2-L
11. Shimada, S.; Maeda, H. A one-pot synthesis of 3-Aminopyridines Chem. Pharm. Bull. 1983, 31, 3460-3464 10.1248/cpb.31.3460
12. Ioerger, T. R.; Feng, Y.; Ganesula, K.; Chen, X.; Dobos, K. M.; Fortune, S.; Jacobs, W. R., Jr.; Mizrahi, V.; Parish, T.; Rubin, E.; Sassetti, C.; Sacchettini, J. C. Variation among genome sequences of H37Rv strains of Mycobacterium tuberculosis from multiple laboratories J. Bacteriol. 2010, 192, 3645-53 10.1128/JB.00166-10
13. Franzblau, S. G.; Witzig, R. S.; McLaughlin, J. C.; Torres, P.; Madico, G.; Hernandez, A.; Degnan, M. T.; Cook, M. B.; Quenzer, V. K.; Ferguson, R. M.; Gilman, R. H. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay J. Clin. Microbiol. 1998, 36, 362-366
14. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. 1st ed.; Academic Press: Waltham, MA, 2008; pp 335-338.
15. Ottaviani, G.; Gosling, D. J.; Patissier, C.; Rodde, S.; Zhou, L.; Faller, B. What is modulating solubility in simulated intestinal fluids? Eur. J. Pharm. Sci. 2010, 41, 452-457 10.1016/j.ejps.2010.07.012
16. Clarysse, S.; Brouwers, J.; Tack, J.; Annaert, P.; Augustijns, P. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids Eur. J. Pharm. Sci. 2011, 43, 260-269 10.1016/j.ejps.2011.04.016
17. Bostrom, J.; Hogner, A.; Llinas, A.; Wellner, E.; Plowright, A. T. Oxadiazoles in medicinal chemistry J. Med. Chem. 2012, 55, 1817-1830 10.1021/jm2013248
18. Collins, L. A.; Torrero, M. N.; Franzblau, S. G. Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis Antimicrob. Agents Chemother. 1998, 42, 344-347
19. Ollinger, J.; Bailey, M. A.; Moraski, G. C.; Casey, A.; Florio, S.; Alling, T.; Miller, M. J.; Parish, T. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis PLoS One 2013, 8, e60531 10.1371/journal.pone.0060531
20. Arora, K.; Ochoa-Montano, B.; Tsang, P. S.; Blundell, T. L.; Dawes, S. S.; Mizrahi, V.; Bayliss, T.; MacKenzie, C. J.; Cleghorn, L. A. T.; Ray, P. C.; Wyatt, P. G.; Uh, E.; Lee, J.; Barry, C. E.; Boshoff, H. I. Respiratory flexibility in response to inhibition of cytochrome c oxidase in Mycobacterium tuberculosis Antimicrob. Agents Chemother. 2014, 58, 6962-6965 10.1128/AAC.03486-14
21. van Embden, J. D. A.; Cave, M. D.; Crawford, J. T.; Dale, J. W.; Eisenach, K. D.; Gicquel, B.; Hermans, P.; Martin, C.; McAdam, R.; Shinnick, T. M.; Small, P. M. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology J. Clin. Microbiol. 1993, 31, 406-409
22. Kamerbeek, J.; Schouls, L.; Kolk, A.; Van Agterveld, M.; Van Soolingen, D.; Kuijper, S.; Bunschoten, A.; Molhuizen, H.; Shaw, R.; Goyal, M.; van Embden, J. Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology J. Clin. Microbiol. 1997, 35, 907-914
23. Streicher, E. M.; Victor, T. C.; van der Spuy, G.; Sola, C.; Rastogi, N.; van Helden, P. D.; Warren, R. M. Spoligotype signatures in the Mycobacterium tuberculosis complex J. Clin. Microbiol. 2007, 45, 237-240 10.1128/JCM.01429-06
24. Balani, S. K.; Li, P.; Nguyen, J.; Cardoza, K.; Zeng, H.; Mu, D. X.; Wu, J. T.; Gan, L. S.; Lee, F. W. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling Drug. Metab. Dispos. 2004, 32, 1092-1095 10.1124/dmd.104.000349
25. Abrahams, K. A.; Cox, J. A.; Spivey, V. L.; Loman, N. J.; Pallen, M. J.; Constantinidou, C.; Fernandez, R.; Alemparte, C.; Remuinan, M. J.; Barros, D.; Ballell, L.; Besra, G. S. Identification of novel imidazo[1,2-A]pyridine inhibitors targeting M. tuberculosis QcrB PLoS One 2012, 7, e52951 10.1371/journal.pone.0052951
26. Kang, S.; Kim, R. Y.; Seo, M. J.; Lee, S.; Kim, Y. M.; Seo, M.; Seo, J. J.; Ko, Y.; Choi, I.; Jang, J.; Nam, J.; Park, S.; Kang, H.; Kim, H. J.; Kim, J.; Ahn, S.; Pethe, K.; Nam, K.; No, Z.; Kim, J. Lead optimization of a novel series of imidazo[1,2-A]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent J. Med. Chem. 2014, 57, 5293-5305 10.1021/jm5003606
27. Moraski, G. C.; Markley, L. D.; Cramer, J.; Hipskind, P. A.; Boshoff, H.; Bailey, M.; Alling, T.; Ollinger, J.; Parish, T.; Miller, M. J. Advancement of imidazo[1,2-A]pyridines with improved pharmacokinetics and nanomolar activity vs. Mycobacterium tuberculosis ACS Med. Chem. Lett. 2013, 4, 675-679 10.1021/ml400088y
28. Moraski, G. C.; Markley, L. D.; Hipskind, P. A.; Boshoff, H.; Cho, S.; Franzblau, S. G.; Miller, M. J. Advent of imidazo[1,2-A]pyridine-3-carboxamides with potent multi- and extended drug resistant antituberculosis activity ACS Med. Chem. Lett. 2011, 2, 466-470 10.1021/ml200036r
29. Pethe, K.; Bifani, P.; Jang, J.; Kang, S.; Park, S.; Ahn, S.; Jiricek, J.; Jung, J.; Jeon, H. K.; Cechetto, J.; Christophe, T.; Lee, H.; Kempf, M.; Jackson, M.; Lenaerts, A. J.; Pham, H.; Jones, V.; Seo, M. J.; Kim, Y. M.; Seo, M.; Seo, J. J.; Park, D.; Ko, Y.; Choi, I.; Kim, R.; Kim, S. Y.; Lim, S.; Yim, S. A.; Nam, J.; Kang, H.; Kwon, H.; Oh, C. T.; Cho, Y.; Jang, Y.; Kim, J.; Chua, A.; Tan, B. H.; Nanjundappa, M. B.; Rao, S. P.; Barnes, W. S.; Wintjens, R.; Walker, J. R.; Alonso, S.; Lee, S.; Kim, J.; Oh, S.; Oh, T.; Nehrbass, U.; Han, S. J.; No, Z.; Lee, J.; Brodin, P.; Cho, S. N.; Nam, K.; Kim, J. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis Nat. Med. 2013, 19, 1157-1160 10.1038/nm.3262
30. Rybniker, J.; Vocat, A.; Sala, C.; Busso, P.; Pojer, F.; Benjak, A.; Cole, S. T. Lansoprazole is an antituberculous prodrug targeting cytochrome bc1 Nat. Commun. 2015, 6, 7659 10.1038/ncomms8659